Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic Equivalence of Fluorouracil Cream 5% in Actinic Keratosis
NCT05078827Phase 3Completed
- Sponsor
- Encube Ethicals
- Start
- Mar 2022
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fluorouracil 5% cream in actinic keratosis (AK) (3 arms), sponsored by Encube Ethicals. Primary endpoints: Therapeutic equivalence with Reference product at 6 weeks, Superiority to Placebo at 6 weeks and 1 more. Started Mar 2022; status: completed.
02
Drugs
fluorouracil 5% cream
03
Conditions
actinic keratosis (AK)
Beyond the preview
Go deeper on NCT05078827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05078827.